1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ji J: Chinese guidelines for diagnosis and
treatment of gastric cancer (2011 edition). Transl Gastrointest
Cancer. 1:103–114. 2012.
|
3
|
Thiery JP: Epithelial-mesenchymal
transitions in tumor progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Herrera V and Parsonnet J: Helicobacter
pylori and gastric adenocarcinoma. Clin Microbiol Infect.
15:971–976. 2009. View Article : Google Scholar
|
5
|
Wright SD, Ramos RA, Tobias PS, Ulevitch
RJ and Mathison JC: CD14, a receptor for complexes of
lipopolysaccharide (LPS) and LPS binding protein. Science.
249:1431–1433. 1990. View Article : Google Scholar : PubMed/NCBI
|
6
|
Pugin J, Heumann ID, Tomasz A, Kravchenko
VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS and Ulevitch RJ:
CD14 is a pattern recognition receptor. Immunity. 1:509–516. 1994.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Chen MC, Chang WW, Kuan YD, Lin ST, Hsu HC
and Lee CH: Resveratrol inhibits LPS-induced epithelial-mesenchymal
transition in mouse melanoma model. Innate Immun. 18:685–693. 2012.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Gioannini TL and Weiss JP: Regulation of
interactions of Gram-negative bacterial endotoxins with mammalian
cells. Immunol Res. 39:249–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
9
|
Miyake K: Innate immune sensing of
pathogens and danger signals by cell surface Toll-like receptors.
Semin Immunol. 19:3–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Zhao D, Sun T, Zhang X, Guo Y, Yu D, Yang
M, Tan W, Wang G and Lin D: Role of CD14 promoter polymorphisms in
Helicobacter pylori infection-related gastric carcinoma.
Clin Cancer Res. 13:2362–2368. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kanczkowski W, Tymoszuk P,
Ehrhart-Bornstein M, Wirth MP, Zacharowski K and Bornstein SR:
Abrogation of TLR4 and CD14 expression and signaling in human
adrenocortical tumors. J Clin Endocrinol Metab. 95:E421–E429. 2010.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Zanoni I, Ostuni R, Capuano G, Collini M,
Caccia M, Ronchi AE, Rocchetti M, Mingozzi F, Foti M, Chirico G,
Costa B, Zaza A, Ricciardi-Castagnoli P and Granucci F: CD14
regulates the dendritic cell life cycle after LPS exposure through
NFAT activation. Nature. 460:264–268. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Reynolds A, Leake D, Boese Q, Scaringe S,
Marshall WS and Khvorova A: Rational siRNA design for RNA
interference. Nat Biotechnol. 22:326–330. 2004. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kawata M, Koinuma D, Ogami T, Umezawa K,
Iwata C, Watabe T and Miyazono K: TGF-β-induced
epithelial-mesenchymal transition of A549 lung adenocarcinoma cells
is enhanced by pro-inflammatory cytokines derived from RAW 264.7
macrophage cells. J Biochem. 151:205–216. 2012.
|
15
|
Bates RC and Mercurio AM: Tumor necrosis
factor-α stimulates the epithelial-to-mesenchymal transition of
human colonic organoids. Mol Biol Cell. 14:1790–1800. 2003.
|
16
|
Guarino M: Epithelial-mesenchymal
transition and tumour invasion. Int J Biochem Cell Biol.
39:2153–2160. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, Kawaguchi Y,
Fujimoto K, Hosotani R and Imamura M: N-cadherin expression and
epithelial-mesenchymal transition in pancreatic carcinoma. Clin
Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
18
|
Cavallaro U, Schaffhauser B and
Christofori G: Cadherins and the tumour progression: is it all in a
switch? Cancer Lett. 176:123–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lang SH, Hyde C, Reid IN, Hitchcock IS,
Hart CA, Bryden AA, Villette JM, Stower MJ and Maitland NJ:
Enhanced expression of vimentin in motile prostate cell lines and
in poorly differentiated and metastatic prostate carcinoma.
Prostate. 52:253–263. 2002. View Article : Google Scholar : PubMed/NCBI
|
20
|
Polk DB and Peek RM Jr: Helicobacter
pylori: gastric cancer and beyond. Nature Rev Cancer.
10:403–414. 2010. View
Article : Google Scholar
|
21
|
Triantafilou M and Triantafilou K: The
dynamics of LPS recognition: complex orchestration of multiple
receptors. J Endotoxin Res. 11:5–11. 2005.PubMed/NCBI
|
22
|
Le Roy D, Di Padova F, Adachi Y, Glauser
MP, Calandra T and Heumann D: Critical role of
lipopolysaccharide-binding protein and CD14 in immune responses
against gram-negative bacteria. J Immunol. 167:2759–2765.
2001.PubMed/NCBI
|
23
|
Schimke J, Mathison J, Morgiewicz J and
Ulevitch RJ: Anti-CD14 mAb treatment provides therapeutic benefit
after in vivo exposure to endotoxin. Proc Natl Acad Sci USA.
95:13875–13880. 1998. View Article : Google Scholar : PubMed/NCBI
|
24
|
Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM
and Zhou BP: Stabilization of snail by NF-κB is required for
inflammation-induced cell migration and invasion. Cancer Cell.
15:416–428. 2009.
|
25
|
Iwano M: EMT and TGF-beta in renal
fibrosis. Front Biosci. 2:229–238. 2010. View
Article : Google Scholar : PubMed/NCBI
|
26
|
Zavadil J and Böttinger EP: TGF-β and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005.
|
27
|
Seki E, De Minicis S, Osterreicher CH,
Kluwe J, Osawa Y, Brenner DA and Schwabe RF: TLR4 enhances TGF-β
signaling and hepatic fibrosis. Nat Med. 13:1324–1332. 2007.
|
28
|
He W, Liu Q, Wang L, Chen W, Li N and Cao
X: TLR4 signaling promotes immune escape of human lung cancer cells
by inducing immunosuppressive cytokines and apoptosis resistance.
Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
29
|
Song MN and Cho SY: CD14 acts as an
angiogenic factor by inducing basic fibroblast growth factor
(bFGF). Bull Korean Chem Soc. 28:1613–1614. 2007. View Article : Google Scholar
|
30
|
Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM,
Chen Y, Qin GJ, Liang G, Li JN, Han XF and Liu DX: Small
interfering RNA-directed targeting of Toll-like receptor 4 inhibits
human prostate cancer cell invasion, survival and tumorigenicity.
Mol Immunol. 46:2876–2884. 2009. View Article : Google Scholar : PubMed/NCBI
|